“The preliminary data generated supports the hypothesis that dosing a substantial proportion of patient’s tumor burden with INT230-6 may cause enough tumor killing and immune activation to provide the patient with extended survival,” said study investigator Anthony El-Khoueiry, MD, Associate Professor of Clinical Medicine, Keck School of Medicine of the University of Southern California and Director of the phase I program at the USC Norris Comprehensive Cancer Center.
“The emerging data shows that the treatment is well tolerated with no patients having to discontinue therapy due to treatment-related toxicities. Observations of tumor shrinkage, tumor necrosis and the regression of uninjected lesions in several patients provide early signs of anti-cancer efficacy. We are looking forward to the emerging data in combination with checkpoint inhibitors.”